Lessons from failure - Preparing for future HIV-1 vaccine efficacy trials

被引：39

作者：

Graham, BS ^{[1
]}

Mascola, JR ^{[1
]}

机构：

[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2005年 / 191卷 / 05期

关键词：

D O I：

10.1086/428406

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：647 / 649

页数：3

共 5 条

[1] HIV preferentially infects HIV-specific CD4+ T cells [J].

Douek, DC ;

Brenchley, JM ;

Betts, MR ;

Ambrozak, DR ;

Hill, BJ ;

Okamoto, Y ;

Casazza, JP ;

Kuruppu, J ;

Kuntsman, K ;

Wolinsky, S ;

Grossman, Z ;

Dybul, M ;

Oxenius, A ;

Price, DA ;

Connors, M ;

Koup, RA .

NATURE, 2002, 417 (6884) :95-98

[2]

Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404

[3] Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial [J].

Gilbert, PB ;

Peterson, ML ;

Follmann, D ;

Hudgens, MG ;

Francis, DP ;

Gurwith, M ;

Heyward, WL ;

Jobes, DV ;

Popovic, V ;

Self, SG ;

Sinangil, F ;

Burke, D ;

Berman, PW .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05) :666-677

[4] AIDS VACCINES - ARE WE READY FOR HUMAN EFFICACY TRIALS [J].

MASCOLA, JR ;

MCNEIL, JG ;

BURKE, DS .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06) :488-489

[5] SUMMARY REPORT - WORKSHOP ON THE POTENTIAL RISKS OF ANTIBODY-DEPENDENT ENHANCEMENT IN HUMAN HIV VACCINE TRIALS [J].

MASCOLA, JR ;

MATHIESON, BJ ;

ZACK, PM ;

WALKER, MC ;

HALSTEAD, SB ;

BURKE, DS .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (12) :1175-1184

← 1 →